Dexmedetomidine transdermal system (DMTS) is a novel transdermal formulation of dexmedetomidine, an alpha-2 adrenergic receptor agonist, being developed by Teikoku Pharma for the treatment of agitation in Alzheimer's disease. This Phase 2 trial represents a novel approach to managing behavioral and psychological symptoms of dementia (BPSD) using a non-oral delivery system.
| Parameter | Value |
|---|---|
| NCT Number | NCT06052254 |
| Phase | Phase 2 |
| Sponsor | Teikoku Pharma Inc. |
| Indication | Agitation associated with Alzheimer's disease |
| Enrollment | 150 participants |
| Status | Enrolling |
| Delivery Method | Transdermal patch |
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist with the following properties:
The transdermal formulation offers several advantages over oral dexmedetomidine:
Agitation is one of the most common and challenging behavioral and psychological symptoms of dementia (BPSD), affecting up to 70% of Alzheimer's patients during disease progression. Current treatment options are limited:
| Current Options | Limitations |
|---|---|
| Atypical antipsychotics | Black box warning for mortality; efficacy marginal |
| Benzodiazepines | Cognitive worsening; fall risk; dependence |
| SSRIs | Delayed onset; GI side effects |
| Acetylcholinesterase inhibitors | Modest efficacy; GI intolerance |
Dexmedetomidine offers a novel mechanism by targeting the noradrenergic system, which is hyperactive in AD-related agitation. The transdermal formulation may provide sustained symptom control with improved tolerability.
The Phase 2 trial likely follows a randomized, double-blind, placebo-controlled design:
Agitation in Alzheimer's disease represents a significant unmet need with several competitors in development:
| Drug | Company | Mechanism | Stage |
|---|---|---|---|
| KarXT | Karuna Therapeutics | M1/M4 muscarinic agonist | Phase 3 (approved as COBENFY™) |
| Nabilone | Corcept Therapeutics | CB1 agonist | Phase 2 |
| Masupirdine | Suven Life Sciences | 5-HT6 antagonist | Phase 2 |
| AVD-104 | Avid Radiopharmaceuticals | Sigma-2 modulator | Phase 2 |
The dexmedetomidine DMTS offers a differentiated mechanism (α2-agonist) and novel delivery method (transdermal).